C

China Medical System Holdings Ltd
SWB:2M7C

Watchlist Manager
China Medical System Holdings Ltd
SWB:2M7C
Watchlist
Price: 1.26 EUR 0.8%
Market Cap: 5.2B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one 2M7C stock under the Base Case scenario is 0.85 EUR. Compared to the current market price of 1.26 EUR, China Medical System Holdings Ltd is Overvalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

2M7C Relative Value
Base Case
0.85 EUR
Overvaluation 33%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

5.8
P/S
P/S
Price to Sales
5.8
vs History
4
vs Industry
31
Median 3Y
3.6
Median 5Y
2.9
Industry
2.5
Forward
5.1
More Details
26.5
P/E
P/E
Price to Earnings
26.5
vs History
0
vs Industry
23
Median 3Y
12.7
Median 5Y
8
Industry
21.1
Forward
25.8
More Details
22.8
P/OCF
P/OCF
Price to OCF
22.8
vs History
0
vs Industry
35
Median 3Y
12.1
Median 5Y
7.8
Industry
16.2
More Details
43.4
P/FCFE
P/FCFE
Price to FCFE
43.4
vs History
0
vs Industry
23
Median 3Y
18.4
Median 5Y
8.7
Industry
23.7
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
9
vs Industry
43
Median 3Y
1.9
Median 5Y
1.6
Industry
2.1
More Details
5
EV/S
EV/S
Enterprise Value to Sales
5
vs History
4
vs Industry
36
Median 3Y
2.9
Median 5Y
2.3
Industry
2.6
Forward
4.4
More Details
6.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.8
vs History
4
vs Industry
46
Median 3Y
3.9
Median 5Y
3.1
Industry
5.1
More Details
23.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
23.2
vs History
0
vs Industry
28
Median 3Y
8.7
Median 5Y
5.5
Industry
12.4
Forward
18.2
More Details
23.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.2
vs History
0
vs Industry
29
Median 3Y
9.4
Median 5Y
5.8
Industry
15.7
Forward
20.2
More Details
19.7
EV/OCF
EV/OCF
Enterprise Value to OCF
19.7
vs History
0
vs Industry
41
Median 3Y
10.2
Median 5Y
6.2
Industry
14.4
More Details
30.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
30.4
vs History
0
vs Industry
32
Median 3Y
11.7
Median 5Y
7.1
Industry
17.1
More Details
3.2
EV/IC
EV/IC
Enterprise Value to IC
3.2
vs History
9
vs Industry
35
Median 3Y
2
Median 5Y
1.7
Industry
1.8
More Details

Multiples Across Competitors

2M7C Competitors Multiples
China Medical System Holdings Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
China Medical System Holdings Ltd
SWB:2M7C
5.2B EUR 5.8 26.5 23.2 23.2
US
Eli Lilly and Co
NYSE:LLY
730.4B USD 14.9 65.8 35.3 38.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
364B USD 4.1 16.7 12.2 16
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.7 19.4 13.5 15.4
CH
Roche Holding AG
SIX:ROG
210.1B CHF 3.5 25.4 9.5 11.2
CH
Novartis AG
SIX:NOVN
188.5B CHF 4.4 18 10.6 14.2
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4 28.3 130.8 197.2
US
Merck & Co Inc
NYSE:MRK
201.7B USD 3.2 11.6 8.6 10.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
136.6B USD 2.2 17.3 7.5 10.5
P/E Multiple
Earnings Growth PEG
HK
C
China Medical System Holdings Ltd
SWB:2M7C
Average P/E: 25.4
26.5
15%
1.8
US
Eli Lilly and Co
NYSE:LLY
65.8
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.7
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.4
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.4
32%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
C
China Medical System Holdings Ltd
SWB:2M7C
Average EV/EBITDA: 396.3
23.2
25%
0.9
US
Eli Lilly and Co
NYSE:LLY
35.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
13%
1
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.6
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
C
China Medical System Holdings Ltd
SWB:2M7C
Average EV/EBIT: 1 699.5
23.2
21%
1.1
US
Eli Lilly and Co
NYSE:LLY
38.6
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.2
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.4
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1

See Also

Summary
2M7C intrinsic value, competitors valuation, and company profile.
DCF Valuation
2M7C stock valuation using Discount Cash Flow valuation method.
Relative Valuation
2M7C stock valuation using valuation multiples.
Wall Street Estimates
2M7C price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
2M7C stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 263,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.